Free Newsletter
Emergent vows to continue battle over collapsed merger
A federal judge has tossed Emergent BioSolutions' attempt to force Protein Sciences into bankruptcy, but Emergent isn't about to give up on its long-running fight with Protein Sciences following the collapse of their merger deal.
These two vaccine companies have been squabbling ever since Emergent's $78 million deal to buy Protein Sciences fell through last year. In this latest round, Emergent says that the judge determined that Protein Sciences was insolvent for not paying its debt in a timely way but felt that Emergent was better off pursuing its lawsuit against the company. Protein Sciences, for its part, says that it tried to repay the $10 million Emergent originally loaned it to get through the merger process, but can't get a response. "It's clear, they want the assets, not the money," Protein Sciences' COO Manon Cox tells the Washington Business Journal.
Protein Sciences' fortunes have changed considerably since the merger pact was signed. The federal government issued a $35 million contract to Protein Sciences to develop new flu vaccine technology. And that contract could potentially be worth $147 million.
- read the story from the Washington Business Journal
Related Articles:
Emergent expands Lansing workforce, facility
Emergent ends attempt to buy Protein Sciences
Emergent accuses biotech execs of wrecking buyout pact (2008)
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: